Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MCA herbal Web site

This article was originally published in The Tan Sheet

Executive Summary

UK Medicines Control Agency launches 1"Herbal safety news" site in late May to provide consumers, practitioners, manufacturers and suppliers with information on safety issues associated with herbal medicines. Online material includes advice on herbal use, safety concerns associated with poor quality of traditional Chinese medicines. Other sections address safety issues for botanicals such as aristolochia, kava, St. John's wort and BotanicLabs' PC-SPES, which was recently recalled due to possible contamination with the Rx drug warfarin (2"The Tan Sheet" May 29, 2002, p. 3)...

You may also be interested in...

NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors

The National Center for Complementary & Alternative Medicine is evaluating the future of multiple PC-SPES studies it is funding following Brea, Calif.-based BotanicLab's recent announcement it is going out of business

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts